Synthesis and Preclinical Evaluation of [ Methylpiperazine - 11 C]brigatinib as a PET Tracer Targeting Both Mutated Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase
Journal of Medicinal Chemistry · 2023
DOI: 10.1021/acs.jmedchem.3c00722 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Antonia A Högnäsbacka und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology & Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081HV Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: H2020 Marie Sklodowska-Curie Actions.
Abstract (Originalsprache)
Brigatinib, a tyrosine kinase inhibitor (TKI) with specificity for gene rearranged anaplastic lymphoma kinase (ALK), such as the EML4-ALK, has shown a potential to inhibit mutated epidermal growth factor receptor (EGFR). In this study, N-desmethyl brigatinib was successfully synthesized as a precursor in five steps. Radiolabeling with [11C]methyl iodide produced [methylpiperazine-11C]brigatinib in a 10 ± 2% radiochemical yield, 91 ± 17 GBq/μmol molar activity, and ≥95% radiochemical purity in 49 ± 4 min. [Methylpiperazine-11C]brigatinib was evaluated in non-small cell lung cancer xenografted female nu/nu mice. An hour post-injection (p.i.), 87% of the total radioactivity in plasma originated from intact [methylpiperazine-11C]brigatinib. Significant differences in tumor uptake were observed between the endogenously EML4-ALK mutated H2228 and the control xenograft A549. The tumor-to-blood ratio in H2228 xenografts could be reduced by pretreatment with ALK inhibitor crizotinib. Tracer uptake in EGFR Del19 mutated HCC827 and EML4-ALK fusion A549 was not significantly different from uptake in A549 xenografts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiology & Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081HV Amsterdam, The Netherlands.
- Biomarkers & Imaging, Cancer Center Amsterdam, Amsterdam, The Netherlands.
ORCID-Profile: Antonia A Högnäsbacka, Wissam Beaino, Danielle J Vugts, Albert D Windhorst
Förderung
- H2020 Marie Sklodowska-Curie Actions
Zitieren
APA
Högnäsbacka, A. A., Poot, A. J., Kooijman, E., Schuit, R. C., Schreurs, M., Verlaan, M., Beaino, W., van Dongen, G. A. M. S., Vugts, D. J., & Windhorst, A. D. (2023). Synthesis and Preclinical Evaluation of [ Methylpiperazine - 11 C]brigatinib as a PET Tracer Targeting Both Mutated Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c00722
Vancouver
Högnäsbacka AA, Poot AJ, Kooijman E, Schuit RC, Schreurs M, Verlaan M, et al. Synthesis and Preclinical Evaluation of [ Methylpiperazine - 11 C]brigatinib as a PET Tracer Targeting Both Mutated Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.3c00722
BibTeX
@article{Hgnsbacka2023,
author = {Högnäsbacka, Antonia A and Poot, Alex J and Kooijman, Esther and Schuit, Robert C and Schreurs, Maxime and Verlaan, Mariska and Beaino, Wissam and van Dongen, Guus A M S and Vugts, Danielle J and Windhorst, Albert D},
title = {Synthesis and Preclinical Evaluation of [ Methylpiperazine - 11 C]brigatinib as a PET Tracer Targeting Both Mutated Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase},
journal = {Journal of Medicinal Chemistry},
year = {2023},
doi = {10.1021/acs.jmedchem.3c00722}
}
EUVIMED